Published in Br J Clin Pharmacol on February 01, 2008
Evidence and Value: Impact on DEcisionMaking--the EVIDEM framework and potential applications. BMC Health Serv Res (2008) 1.66
Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients. Cost Eff Resour Alloc (2010) 1.30
Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa. Cost Eff Resour Alloc (2012) 0.93
Money makes the world go round: the pervasiveness of pharmacoeconomics. Br J Clin Pharmacol (2008) 0.82
Sensitivity: real (interferons, odorants) and imagined (homeopathy). Br J Clin Pharmacol (2008) 0.78
Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA (1998) 12.60
National Institute for Clinical Excellence and its value judgments. BMJ (2004) 8.97
The influence of the probability of survival on patients' preferences regarding cardiopulmonary resuscitation. N Engl J Med (1994) 6.39
Public involvement in health care. BMJ (2004) 4.99
Ethical considerations in the allocation of organs and other scarce medical resources among patients. Council on Ethical and Judicial Affairs, American Medical Association. Arch Intern Med (1995) 1.90
Assessing priorities for allocation of donor liver grafts: survey of public and clinicians. BMJ (1998) 1.88
Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared. Health Policy (2005) 1.48
Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ (2004) 1.42
Pharmacopolitics and deliberative democracy. Clin Med (2005) 1.36
Disease gravity and urgency of need as guidelines for liver allocation. Hepatology (1994) 1.16
Prognosis without treatment as a modifier in health economic assessments. BMJ (2005) 1.02
Doctors should not discuss resuscitation with terminally ill patients: FOR. BMJ (2003) 0.92
Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med (2005) 6.22
A prescription for better prescribing. BMJ (2006) 5.31
A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr (2007) 4.34
Clinical pharmacology--too young to die? Lancet (2006) 4.32
Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology (2011) 4.06
Undergraduate preparation for prescribing: the views of 2413 UK medical students and recent graduates. Br J Clin Pharmacol (2008) 3.52
Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol (2003) 3.37
The revision of the Declaration of Helsinki: past, present and future. Br J Clin Pharmacol (2004) 3.35
Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension (2009) 2.38
A spoonful of sugar? Tomorrow's doctors 2002. Br J Clin Pharmacol (2002) 2.32
Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension (2006) 2.30
Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology (2013) 2.24
Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol (2006) 2.19
Increased central pulse pressure and augmentation index in subjects with hypercholesterolemia. J Am Coll Cardiol (2002) 2.14
Nitric oxide regulates local arterial distensibility in vivo. Circulation (2002) 2.04
Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity. Atherosclerosis (2011) 1.80
Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes (2006) 1.79
COX-2 selective inhibitors--important lessons learned. Lancet (2005) 1.74
Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J Transl Med (2012) 1.70
Heart rate dependency of pulse pressure amplification and arterial stiffness. Am J Hypertens (2002) 1.66
Cyclophilin A is a damage-associated molecular pattern molecule that mediates acetaminophen-induced liver injury. J Immunol (2011) 1.63
Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol (2012) 1.61
Perceived causes of prescribing errors by junior doctors in hospital inpatients: a study from the PROTECT programme. BMJ Qual Saf (2012) 1.61
Learning curves, taking instructions, and patient safety: using a theoretical domains framework in an interview study to investigate prescribing errors among trainee doctors. Implement Sci (2012) 1.60
Impact on hypertension control of a patient-held guideline: a randomised controlled trial. Br J Gen Pract (2006) 1.56
Poor prescribing is continual. BMJ (2006) 1.55
Non-invasive measurement of cardiac output in patients with chronic heart failure. Blood Press Monit (2004) 1.51
Oxidized phospholipid inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition. J Biol Chem (2008) 1.48
Medical students' perceptions and knowledge about antimicrobial stewardship: how are we educating our future prescribers? Clin Infect Dis (2013) 1.47
Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans. J Am Coll Cardiol (2008) 1.47
Non-endothelial cell endothelin-B receptors limit neointima formation following vascular injury. Cardiovasc Res (2012) 1.46
New guidelines for drive-by renal arteriography may lead to an unjustifiable increase in percutaneous intervention. Heart (2007) 1.46
Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension (2009) 1.46
Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension. Hypertension (2010) 1.45
Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. Br J Clin Pharmacol (2002) 1.42
The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol (2006) 1.42
Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis. Am J Gastroenterol (2004) 1.41
Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol (2002) 1.40
Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. Crit Care Med (2007) 1.40
Nitric oxide and the regulation of arterial elasticity: right idea, wrong vascular bed? Hypertension (2002) 1.38
Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res (2010) 1.37
Vascular effects of apelin in vivo in man. J Am Coll Cardiol (2008) 1.33
Strain and temperature sensitivity of a single-mode polymer optical fiber. Opt Lett (2005) 1.33
Exosomal transmission of functional aquaporin 2 in kidney cortical collecting duct cells. J Physiol (2011) 1.32
Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med (Maywood) (2006) 1.31
Quantification of human urinary exosomes by nanoparticle tracking analysis. J Physiol (2013) 1.31
Arterial stiffness and hypertension: emerging concepts. Hypertension (2009) 1.30
Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia (2005) 1.28
Blood markers of coagulation, fibrinolysis, endothelial dysfunction and inflammation in lacunar stroke versus non-lacunar stroke and non-stroke: systematic review and meta-analysis. Cerebrovasc Dis (2013) 1.28
Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation (2004) 1.27
Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. Hypertension (2006) 1.26
Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler Thromb Vasc Biol (2005) 1.24
Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol (2009) 1.19
Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology (2002) 1.18
Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors. Clin Cancer Res (2009) 1.16
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol (2009) 1.15
Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension (2011) 1.15
Educating European (junior) doctors for safe prescribing. Basic Clin Pharmacol Toxicol (2007) 1.15
Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products. Br J Clin Pharmacol (2006) 1.13
Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension (2008) 1.13
The road from AKI to CKD: the role of endothelin. Kidney Int (2013) 1.09
Impact of a focussed teaching programme on practical prescribing skills among final year medical students. Br J Clin Pharmacol (2011) 1.09
Cardiovascular effects of acute oxygen administration in healthy adults. J Cardiovasc Pharmacol (2003) 1.08
Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am J Physiol Renal Physiol (2009) 1.06
Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease. J Alzheimers Dis (2008) 1.05
Junior doctors' perceptions of their self-efficacy in prescribing, their prescribing errors and the possible causes of errors. Br J Clin Pharmacol (2013) 1.05
Endogenous endothelin-1 limits exercise-induced vasodilation in hypertensive humans. Hypertension (2002) 1.03
Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Mol Biosyst (2012) 1.02
Vessel wall stiffness in type 1 diabetes and the central hemodynamic effects of acute hypoglycemia. Am J Physiol Endocrinol Metab (2007) 1.02
Prognosis without treatment as a modifier in health economic assessments. BMJ (2005) 1.02
Continuous wave ultraviolet light-induced fiber Bragg gratings in few- and single-mode microstructured polymer optical fibers. Opt Lett (2005) 1.02
γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000). Clin Cancer Res (2012) 1.02
Nebivolol increases arterial distensibility in vivo. Hypertension (2004) 0.99
Clinical trials of endothelin antagonists in heart failure: a question of dose? Exp Biol Med (Maywood) (2006) 0.99
Developing and piloting a nurse-led model of follow-up in the multidisciplinary management of colorectal cancer. Eur J Oncol Nurs (2006) 0.98
Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies. Clin Drug Investig (2008) 0.97
Humidity insensitive TOPAS polymer fiber Bragg grating sensor. Opt Express (2011) 0.97
Letter by Payne and Webb regarding article, "agreement among cardiovascular disease risk calculators". Circulation (2013) 0.97
Endothelium-derived endothelin-1. Pflugers Arch (2009) 0.97
Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol (2005) 0.96
High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res (2002) 0.95
Quantitative 3-dimensional imaging of murine neointimal and atherosclerotic lesions by optical projection tomography. PLoS One (2011) 0.95
Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci (2007) 0.93
Nitric oxide donor drugs: current status and future trends. Expert Opin Investig Drugs (2002) 0.93
Potential therapeutic role of phosphodiesterase type 5 inhibition in hypertension and chronic kidney disease. Hypertension (2013) 0.92
Oxygen therapy in acute medical care. BMJ (2002) 0.91
Effects of antiplatelet components of tomato extract on platelet function in vitro and ex vivo: a time-course cannulation study in healthy humans. Am J Clin Nutr (2006) 0.91
Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. J Am Soc Nephrol (2012) 0.91
Systemic and regional changes in plasma endothelin following transient increase in portal pressure. Liver Transpl (2003) 0.91
Toll-like receptor 4 signalling is neither sufficient nor required for oxidised phospholipid mediated induction of interleukin-8 expression. Atherosclerosis (2006) 0.90
No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol (2002) 0.90
Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro. Cancer Chemother Pharmacol (2008) 0.90